Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.56EUR
−103.04 MEUR
114.45 MEUR
119.86 M
About Seres Therapeutics, Inc.
Sector
Industry
CEO
Eric D. Shaff
Website
Headquarters
Cambridge
Employees (FY)
233
Founded
2010
FIGI
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 1S9 is 0.71 EUR — it has decreased by 0.70% in the past 24 hours. Watch SERES THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange SERES THERAPEUTICS INC stocks are traded under the ticker 1S9.
1S9 stock has fallen by 1.64% compared to the previous week, the month change is a 18.75% fall, over the last year SERES THERAPEUTICS INC has showed a 43.89% decrease.
We've gathered analysts' opinions on SERES THERAPEUTICS INC future price: according to them, 1S9 price has a max estimate of 9.20 EUR and a min estimate of 0.92 EUR. Watch 1S9 chart and read a more detailed SERES THERAPEUTICS INC stock forecast: see what analysts think of SERES THERAPEUTICS INC and suggest that you do with its stocks.
1S9 stock is 2.26% volatile and has beta coefficient of 1.68. Track SERES THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is SERES THERAPEUTICS INC there?
Today SERES THERAPEUTICS INC has the market capitalization of 102.42 M, it has increased by 6.91% over the last week.
Yes, you can track SERES THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
SERES THERAPEUTICS INC is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
1S9 earnings for the last quarter are −0.25 EUR per share, whereas the estimation was −0.32 EUR resulting in a 20.98% surprise. The estimated earnings for the next quarter are −0.25 EUR per share. See more details about SERES THERAPEUTICS INC earnings.
SERES THERAPEUTICS INC revenue for the last quarter amounts to 0 EUR, despite the estimated figure of 231.70 K EUR. In the next quarter, revenue is expected to reach −246.50 K EUR.
1S9 net income for the last quarter is −37.19 M EUR, while the quarter before that showed −37.37 M EUR of net income which accounts for 0.47% change. Track more SERES THERAPEUTICS INC financial stats to get the full picture.
No, 1S9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 30, 2024, the company has 233.00 employees. See our rating of the largest employees — is SERES THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SERES THERAPEUTICS INC EBITDA is −59.58 M EUR, and current EBITDA margin is −72.96%. See more stats in SERES THERAPEUTICS INC financial statements.
Like other stocks, 1S9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SERES THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.